Are you sure you want to leave this page

If you leave now, your registration will be incomplete, and the information you have input so far will not be saved. It also means you will not be able to start orders or view important information within your portal account.

Adding a New Shipping Location

Note: For this order, you can only include Shipping Locations that are already confirmed on your Seqirus account.

To add a new Shipping Location to your account, click "Add New Location" below. Our team will review and approve the new location, which can take up to 5 business days. Once approved, you can place an order using the new location.

  1. Home /
  2. About Us

ABOUT
SEQIRUS

Seqirus is a leader in the fight against influenza with an innovative portfolio of influenza products. With over a century's worth of commitment to influenza combined with robust, global manufacturing capabilities, Seqirus is a go-to partner for you.

Expertise Through Experience

With more than a century's worth of experience established by Commonwealth Serum Laboratories, Seqirus has been on the front line of the fight against influenza. Our long history begins with the 1918 Spanish Influenza Pandemic and continues today with the discovery and development of breakthrough innovations in influenza prevention.1,2

1916
  1. lorem ipsum 1916
  2. 1918
  3. 1933
  4. 1944
  5. lorem ipsum 1951
  6. 1957
  7. 1968
  8. lorem ipsum 1973
  9. 1978
  10. 1992
  11. lorem ipsum 1994
  12. lorem ipsum 2009
  13. 2012
  14. lorem ipsum 2015
  15. lorem ipsum 2016

  1. 1916: Founded on Quality

    The Commonwealth Serum Laboratories — now known as CSL Limited — is founded in Australia, with renowned bacteriologist Dr. William Penfold serving as the first director. His founding principle: the organization will “live or die by the quality of its products.”4

  2. 1916: Founded on Quality

    The Commonwealth Serum Laboratories — now known as CSL Limited — is founded in Australia, with renowned bacteriologist Dr. William Penfold serving as the first director. His founding principle: the organization will “live or die by the quality of its products.”4

  3. 1918-1919: Fighting Spanish Influenza

    After causing millions of deaths around the world, the Spanish influenza pandemic strikes Australia. CSL rapidly produces 3 million doses of a mixed bacterial vaccine, later shown to have effectively combatted the complications of the disease.4

  4. 1933: Breakthrough in Influenza Understanding

    Scientists at the National Institute for Medical Research in London discover viruses cause influenza — not bacteria.4

  5. 1944: Fighting the Influenza Virus

    CSL begins production on egg-based influenza vaccines in order to supply one million doses to Australian and British troops. The egg-based method of production is developed from the pioneering work of Macfarlane Burnet, a scientist at the Walter and Eliza Hall Institute of Medical Research.4

  6. 1951: Global Influenza Network

    The World Health Organization designates CSL as an Influenza Reference Laboratory, recognizing its technical capabilities and the importance of the Southern Hemisphere in observing the ever-changing influenza virus.4

  7. 1957-1958: Asian Influenza Pandemic

    CSL responds quickly to protect Australians from the Asian influenza pandemic, producing 1.6 million doses of pandemic vaccine.4

  8. 1968-1969: Hong Kong Influenza Pandemic

    CSL produces 5 million doses of a pandemic vaccine for Australians to fight against the emerging Hong Kong influenza pandemic. Following the pandemic, CSL uses new resources to invest in its production process and improve its seasonal influenza vaccine.4

  9. 1973: Technical Expertise in Influenza

    CSL begins to adapt (re-assort) influenza strains to grow better in eggs, providing the resulting “manufacturing seeds” to the WHO each season. The WHO then shares the seeds with all manufacturers worldwide for vaccine production.4

  10. 1978: Fighting More Strains of Influenza

    CSL transitions its seasonal influenza vaccine from bivalent (2 strain) to trivalent (3 strain).4

  11. 1992: WHO Influenza Designation

    CSL becomes a WHO Influenza Collaborating Centre, strengthening the organization’s role in the global influenza network.4

  12. 1994: International Expansion

    CSL acquires a United States-based cell culture company, JRH Biosciences, beginning expansion to the United States and Europe.4

  13. 2009: H1N1 Response

    As the H1N1 influenza pandemic accelerates, CSL's rapid response equips Australia to deliver influenza vaccines quickly to its vulnerable population — one of the first countries in the world to do so.2,3

    Introducing Cell Culture Influenza Vaccines

    As part of pandemic preparedness plans, Novartis Influenza Vaccines, later acquired by CSL, and the United States government announce the construction of a state-of-the-art manufacturing facility where the first approved cell-culture influenza vaccine would be produced.4

  14. 2012: Business Reorganization in Australia

    CSL creates bioCSL, a stand-alone business unit dedicated to vaccines, pharmaceuticals, and diagnostics.4

  15. 2015: Becoming Seqirus

    CSL acquires and combines the Novartis Influenza Vaccine business with bioCSL to form Seqirus, the second-largest Influenza Vaccine manufacturer in the world. Following the integration, Seqirus expands production capacity to better meet global demand.1

    2015: Influenza Vaccine Innovations

    Seqirus receives FDA approval for FLUAD® (Influenza Vaccine, Adjuvanted), the first adjuvanted seasonal influenza vaccine, which gives Seqirus a differentiating product in its portfolio. Seqirus also completes significant regulatory submissions for the approval of quadrivalent influenza vaccines.4,5

    2015: Diversifying the Portfolio

    CSL acquires the rights to commercialize RAPIVABTM (peramivir injection), an IV treatment for acute uncomplicated influenza.4

  16. 2016: An FDA-Approved Cell Culture-Derived Quadrivalent Influenza Vaccine

    The FDA approves FLUCELVAX® QUADRIVALENT (Influenza Vaccine), the first 4-strain, cell culture-derived, inactivated seasonal influenza vaccine.4,6

    2016: A Century on the Front Line of Fighting Influenza

    Seqirus is a leading manufacturer and supplier of influenza vaccines globally. Our global network includes manufacturing sites on 3 continents, research and development practices, and a commercial presence in 20 countries. Our 3,000+ employees are passionate, skilled experts who are driven to save as many lives as possible in the fight against influenza.2

References

  1. CSL. 100 years and just getting started. https://www.csl.com/en-us/our-company/our-story/celebrating-100-years. Accessed October 25, 2018.
  2. About us. Seqirus website. https://www.seqirus.com/about. Accessed October 25, 2018.
  3. US Department of Health and Human Services. First U.S. cell-based flu vaccine plant set for dedication facility's ability to produce cell-based pandemic flu vaccine marks historic change. https://www.phe.gov/Preparedness/new/Pages/cellflu-111212.aspx. Published December 12, 2011. Accessed September 28, 2018.
  4. CSL: 100 Years Timeline Booklet. 2016.
  5. Centers for Disease Control and Prevention. Flu vaccine with adjuvant, brand name FLUAD. https://www.cdc.gov/flu/protect/vaccine/adjuvant.htm. Updated October 18, 2018. Accessed October 25, 2018.
  6. Centers for Disease Control and Prevention. Cell-based flu vaccines. https://www.cdc.gov/flu/protect/vaccine/cell-based.htm. Updated October 4, 2018. Accessed October 25, 2018.

LEARN.
ORDER.
MANAGE.

By creating an account with us, you can see specific product
pricing, make a purchase, and manage your shipments easily.